181 related articles for article (PubMed ID: 26158134)
1. Systemic Therapy for Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck.
Colevas AD
J Natl Compr Canc Netw; 2015 May; 13(5):e37-48. PubMed ID: 26158134
[TBL] [Abstract][Full Text] [Related]
2. Current treatment options for metastatic head and neck cancer.
Price KA; Cohen EE
Curr Treat Options Oncol; 2012 Mar; 13(1):35-46. PubMed ID: 22252884
[TBL] [Abstract][Full Text] [Related]
3. Phase II clinical study of valproic acid plus cisplatin and cetuximab in recurrent and/or metastatic squamous cell carcinoma of Head and Neck-V-CHANCE trial.
Caponigro F; Di Gennaro E; Ionna F; Longo F; Aversa C; Pavone E; Maglione MG; Di Marzo M; Muto P; Cavalcanti E; Petrillo A; Sandomenico F; Maiolino P; D'Aniello R; Botti G; De Cecio R; Losito NS; Scala S; Trotta A; Zotti AI; Bruzzese F; Daponte A; Calogero E; Montano M; Pontone M; De Feo G; Perri F; Budillon A
BMC Cancer; 2016 Nov; 16(1):918. PubMed ID: 27884140
[TBL] [Abstract][Full Text] [Related]
4. Current chemotherapies for recurrent/metastatic head and neck cancer.
Molin Y; Fayette J
Anticancer Drugs; 2011 Aug; 22(7):621-5. PubMed ID: 21131821
[TBL] [Abstract][Full Text] [Related]
5. Optimal treatment for recurrent/metastatic head and neck cancer.
Vermorken JB; Specenier P
Ann Oncol; 2010 Oct; 21 Suppl 7():vii252-61. PubMed ID: 20943624
[TBL] [Abstract][Full Text] [Related]
6. Chemotherapy options for patients with metastatic or recurrent squamous cell carcinoma of the head and neck.
Colevas AD
J Clin Oncol; 2006 Jun; 24(17):2644-52. PubMed ID: 16763278
[TBL] [Abstract][Full Text] [Related]
7. Molecularly targeted agents in the treatment of recurrent or metastatic squamous cell carcinomas of the head and neck.
Le Tourneau C; Chen EX
Hematol Oncol Clin North Am; 2008 Dec; 22(6):1209-20, ix. PubMed ID: 19010269
[TBL] [Abstract][Full Text] [Related]
8. Capecitabine and lapatinib for the first-line treatment of metastatic/recurrent head and neck squamous cell carcinoma.
Weiss JM; Bagley S; Hwang WT; Bauml J; Olson JG; Cohen RB; Hayes DN; Langer C
Cancer; 2016 Aug; 122(15):2350-5. PubMed ID: 27197056
[TBL] [Abstract][Full Text] [Related]
9. Current recommendations for systemic therapy of recurrent and/or metastatic head and neck squamous cell cancer.
Fury MG; Pfister DG
J Natl Compr Canc Netw; 2011 Jun; 9(6):681-9. PubMed ID: 21636539
[TBL] [Abstract][Full Text] [Related]
10. Optimizing treatments for recurrent or metastatic head and neck squamous cell carcinoma.
Specenier P; Vermorken JB
Expert Rev Anticancer Ther; 2018 Sep; 18(9):901-915. PubMed ID: 29999437
[TBL] [Abstract][Full Text] [Related]
11. Clinical outcomes of platinum-based chemotherapy plus cetuximab for recurrent or metastatic squamous cell carcinoma of the head and neck: comparison between platinum-sensitive and platinum-resistant patients.
Sato H; Tsukahara K; Okamoto I; Katsube Y; Shimizu A; Kondo T; Hanyu K; Fushimi C; Okada T; Miura K
Acta Otolaryngol; 2019 Feb; 139(2):201-205. PubMed ID: 30794080
[TBL] [Abstract][Full Text] [Related]
12. Chemotherapy for recurrent/metastatic head and neck cancers.
Karabajakian A; Toussaint P; Neidhardt EM; Paulus V; Saintigny P; Fayette J
Anticancer Drugs; 2017 Apr; 28(4):357-361. PubMed ID: 28166090
[TBL] [Abstract][Full Text] [Related]
13. Prognostic score in patients with recurrent or metastatic carcinoma of the head and neck treated with cetuximab and chemotherapy.
Magnes T; Melchardt T; Weiss L; Mittermair C; Neureiter D; Klieser E; Gampenrieder S; Moser G; Gaggl A; Greil R; Egle A
PLoS One; 2017; 12(7):e0180995. PubMed ID: 28686697
[TBL] [Abstract][Full Text] [Related]
14. Phase Ib study of duligotuzumab (MEHD7945A) plus cisplatin/5-fluorouracil or carboplatin/paclitaxel for first-line treatment of recurrent/metastatic squamous cell carcinoma of the head and neck.
Jimeno A; Machiels JP; Wirth L; Specenier P; Seiwert TY; Mardjuadi F; Wang X; Kapp AV; Royer-Joo S; Penuel E; McCall B; Pirzkall A; Clement PM
Cancer; 2016 Dec; 122(24):3803-3811. PubMed ID: 27525588
[TBL] [Abstract][Full Text] [Related]
15. PARTNER: An open-label, randomized, phase 2 study of docetaxel/cisplatin chemotherapy with or without panitumumab as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck.
Wirth LJ; Dakhil S; Kornek G; Axelrod R; Adkins D; Pant S; O'Brien P; Debruyne PR; Oliner KS; Dong J; Murugappan S
Oral Oncol; 2016 Oct; 61():31-40. PubMed ID: 27688102
[TBL] [Abstract][Full Text] [Related]
16. The Evolving and Future Role of Taxanes in Squamous Cell Carcinomas of the Head and Neck: A Review.
Mody MD; Gill HS; Saba NF
JAMA Otolaryngol Head Neck Surg; 2016 Sep; 142(9):898-905. PubMed ID: 27389786
[TBL] [Abstract][Full Text] [Related]
17. Cost-Effectiveness of Nivolumab in Recurrent Metastatic Head and Neck Squamous Cell Carcinoma.
Zargar M; McFarlane T; Chan KKW; Wong WWL
Oncologist; 2018 Feb; 23(2):225-233. PubMed ID: 29021380
[TBL] [Abstract][Full Text] [Related]
18. Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial.
Harrington KJ; Ferris RL; Blumenschein G; Colevas AD; Fayette J; Licitra L; Kasper S; Even C; Vokes EE; Worden F; Saba NF; Kiyota N; Haddad R; Tahara M; Grünwald V; Shaw JW; Monga M; Lynch M; Taylor F; DeRosa M; Morrissey L; Cocks K; Gillison ML; Guigay J
Lancet Oncol; 2017 Aug; 18(8):1104-1115. PubMed ID: 28651929
[TBL] [Abstract][Full Text] [Related]
19. Current Treatment Options for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.
Sacco AG; Cohen EE
J Clin Oncol; 2015 Oct; 33(29):3305-13. PubMed ID: 26351341
[TBL] [Abstract][Full Text] [Related]
20. New drug therapy for squamous carcinoma of the head and neck.
Murphy BA
Curr Opin Oncol; 1996 May; 8(3):221-6. PubMed ID: 8794150
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
